Apellis Pharmaceuticals, Inc. - Common Stock (APLS)
29.01
-1.38 (-4.54%)
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapies for the treatment of serious diseases through its expertise in complement biology
The company works on advancing its proprietary drug candidates designed to modulate the immune system, with particular attention to rare and complex conditions that currently have limited treatment options. By harnessing advanced science and technology, Apellis aims to improve patient outcomes and address unmet medical needs in various therapeutic areas, including hematology and ophthalmology.
William Blair initiates coverage of Apellis Pharmaceuticals, highlighting its innovative therapies for complement C3 targeting. The analyst forecasts significant growth opportunities with peak sales estimates of $700 million by 2031 for Empaveli and $2 billion for Syfovre by 2030.
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following re-examination.
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary endpoints, showing proteinuria and kidney inflammation reductions.
